<?xml version="1.0" encoding="UTF-8"?>
<Label drug="mentax" track="TAC2017_ADR">
  <Text>
    <Section name="adverse reactions" id="S1">    ADVERSE REACTIONS

  In controlled clinical trials, 9 (approximately 1%) of 815 patients treated with Mentax  (r)  Cream, 1%, reported adverse events related to the skin. These included burning/stinging, itching and worsening of the condition. No patient treated with Mentax  (r)  Cream, 1%, discontinued treatment due to an adverse event. In the vehicle-treated patients, 2 of 718 patients discontinued because of treatment site adverse events, one of which was severe burning/stinging and itching at the site of application.



 In uncontrolled clinical trials, the most frequently reported adverse events in patients treated with Mentax(r) Cream, 1%, were: contact dermatitis, erythema, irritation, and itching, each occurring in less than 2% of patients.



 In provocative testing in over 200 subjects, there was no evidence of allergic-contact sensitization for either cream or vehicle base for Mentax  (r)  Cream, 1%.
</Section>
  </Text>
  <Mentions />
  <Relations />
  <Reactions />
</Label>
